Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial

Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial

Osama Sawalmeh,1 Shaheed Moala,1 Zakaria Hamdan,2 Huda Masri,3 Khubaib Ayoub,4 Emad Khazneh,2 Mujahed Shraim5 1Medicine Department, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine; 2Nephrology Department, 3Pharmacy Department, 4Internal Medicine Department, A...

Full description

Bibliographic Details
Main Authors: Sawalmeh O, Moala S, Hamdan Z, Masri H, Ayoub K, Khazneh E, Shraim M
Format: Article
Language:English
Published: Dove Medical Press 2018-01-01
Series:International Journal of Nephrology and Renovascular Disease
Subjects:
end stage kidney disease
hemodialysis
alphacalcidol
parathyroid hormone
hyperparathyroidism
randomized controlled trials
Online Access:https://www.dovepress.com/pulse-versus-daily-oral-alfacalcidol-treatment-of-secondary-hyperparat-peer-reviewed-article-IJNRD

Internet

https://www.dovepress.com/pulse-versus-daily-oral-alfacalcidol-treatment-of-secondary-hyperparat-peer-reviewed-article-IJNRD

Similar Items